Tle3 as a marker for chemotherapy

Abstract

Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.

1 . (canceled) 
     
     
         2 . A method of identifying a breast cancer that will not respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
 (a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;   (b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is lower than a reference; and   (c) identifying the patient's breast cancer as one that will not respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative,   wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with an antibody that binds TLE3 polypeptide thereby forming a complex comprising the antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.   
     
     
         3 . The method of  claim 2 , wherein the step of detecting comprises quantifying a percentage of cells in which immunohistochemical staining for TLE3 polypeptide is detected. 
     
     
         4 . The method of  claim 2 , wherein the step of detecting comprises quantifying an intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample. 
     
     
         5 . The method of  claim 2 , wherein the step of identifying comprises identifying the patient's breast cancer as one that will not respond favorably to a chemotherapy treatment that includes a taxane. 
     
     
         6 . The method of  claim 5 , wherein the taxane is paclitaxel or docetaxel. 
     
     
         7 . The method of  claim 2 , further comprising administering a chemotherapy treatment that does not include a taxane or taxane derivative to the breast cancer patient. 
     
     
         8 . A method of identifying a breast cancer that will not respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
 (a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;   (b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is lower than a reference; and   (c) identifying the patient's breast cancer as one that will not respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative,   wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with a primary antibody that binds TLE3 polypeptide and a labeled secondary antibody that binds the primary antibody thereby forming a complex comprising the primary antibody, secondary antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.   
     
     
         9 . The method of  claim 8 , wherein the step of detecting comprises quantifying a percentage of cells in which immunohistochemical staining for TLE3 polypeptide is detected. 
     
     
         10 . The method of  claim 8 , wherein the step of detecting comprises quantifying an intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample. 
     
     
         11 . The method of  claim 8 , wherein the step of identifying comprises identifying the patient's breast cancer as one that will not respond favorably to a chemotherapy treatment that includes a taxane. 
     
     
         12 . The method of  claim 11 , wherein the taxane is paclitaxel or docetaxel. 
     
     
         13 . The method of  claim 8 , further comprising administering a chemotherapy treatment that does not include a taxane or taxane derivative to the breast cancer patient. 
     
     
         14 . A method of predicting the likelihood that a breast cancer will not respond to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
 (a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;   (b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is lower than a reference; and   (c) predicting that the patient's breast cancer will likely not respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative,   wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with an antibody that binds TLE3 polypeptide thereby forming a complex comprising the antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.   
     
     
         15 . The method of  claim 14 , wherein the step of detecting comprises quantifying a percentage of cells in which immunohistochemical staining for TLE3 polypeptide is detected. 
     
     
         16 . The method of  claim 14 , wherein the step of detecting comprises quantifying an intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample. 
     
     
         17 . The method of  claim 14 , wherein the step of predicting comprises predicting that the patient's breast cancer will likely not respond to a chemotherapy treatment that includes a taxane. 
     
     
         18 . The method of  claim 17 , wherein the taxane is paclitaxel. 
     
     
         19 . The method of  claim 17 , wherein the taxane is docetaxel. 
     
     
         20 . The method of  claim 14 , further comprising administering a chemotherapy treatment that does not include a taxane or taxane derivative to the breast cancer patient.